Single-Cell XIST Expression in Human Preimplantation Embryos and Newly Reprogrammed Female Induced Pluripotent Stem Cells

Stem Cells
Sharon F BriggsRenee A Reijo Pera

Abstract

The process of X chromosome inactivation (XCI) during reprogramming to produce human induced pluripotent stem cells (iPSCs), as well as during the extensive programming that occurs in human preimplantation development, is not well-understood. Indeed, studies of XCI during reprogramming to iPSCs report cells with two active X chromosomes and/or cells with one inactive X chromosome. Here, we examine expression of the long noncoding RNA, XIST, in single cells of human embryos through the oocyte-to-embryo transition and in new mRNA reprogrammed iPSCs. We show that XIST is first expressed beginning at the 4-cell stage, coincident with the onset of embryonic genome activation in an asynchronous manner. Additionally, we report that mRNA reprogramming produces iPSCs that initially express XIST transcript; however, expression is rapidly lost with culture. Loss of XIST and H3K27me3 enrichment at the inactive X chromosome at late passage results in X chromosome expression changes. Our data may contribute to applications in disease modeling and potential translational applications of female stem cells.

References

Jan 11, 1996·Nature·G D PennyN Brockdorff
Jan 15, 1997·Genes & Development·Y MarahrensR Jaenisch
Jul 1, 1997·American Journal of Human Genetics·C J Brown, W P Robinson
Jul 1, 1997·American Journal of Human Genetics·R DanielsM Monk
Jan 31, 2004·Science·Winifred MakNeil Brockdorff
May 20, 2004·Human Molecular Genetics·Anthony T DobsonRenee A Reijo Pera
Sep 15, 2005·Human Molecular Genetics·Tariq EnverPeter W Andrews
Mar 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Susana S SilvaJeannie T Lee
Jun 2, 2009·American Journal of Human Genetics·Ilse M van den BergJ Hikke van Doorninck
Aug 24, 2010·Cell Stem Cell·Jason TchieuKathrin Plath
Feb 15, 2011·The Journal of Clinical Investigation·Kazim H NarsinhJoseph C Wu
Apr 9, 2011·Cell Stem Cell·Tasha KalistaChristopher Thomas Scott
Jul 14, 2011·European Journal of Human Genetics : EJHG·Mariangela AmenduniIlaria Meloni
May 9, 2012·Cell Stem Cell·Shila MekhoubadKevin Eggan
Dec 6, 2012·Nature Communications·Shawn L ChavezRenee A Reijo Pera
May 16, 2013·Nature Reviews. Molecular Cell Biology·Patrick Cahan, George Q Daley
May 14, 2014·Human Molecular Genetics·Shawn L ChavezRenee A Reijo Pera

❮ Previous
Next ❯

Citations

Feb 18, 2016·Stem Cells International·Shanshan Hu, Ge Shan
Mar 18, 2016·Archives of Oral Biology·Yunfei Zheng, Lingfei Jia
Oct 7, 2016·Frontiers in Bioengineering and Biotechnology·Naveen RamalingamJay A A West
Mar 31, 2019·Epigenetics : Official Journal of the DNA Methylation Society·Anelise Dos Santos MendonçaMaurício Machaim Franco
Sep 28, 2017·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Anna SahakyanClaire Rougeulle
Sep 25, 2019·Genome Research·Abigail F GroffKevin Eggan
Jan 8, 2020·International Journal of Molecular Sciences·Enrico AlessioStefano Cagnin
Jan 5, 2020·Development·Catherine PatratClaire Rougeulle
May 30, 2017·Frontiers in Genetics·Rosalia BattagliaCinzia Di Pietro
Oct 7, 2020·Annual Review of Cell and Developmental Biology·Claudia GerriKathy K Niakan
Feb 17, 2021·Médecine sciences : M/S·Madeleine Moscatelli, Claire Rougeulle
Apr 20, 2021·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Aline MuyleJames M A Turner

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
transfection
electron microscopy
chip
FACS
transfections

Software Mentioned

ImageJ
Excel

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.